Silverarc Capital Management’s Faeth Therapeutics FTH Stock Holding History

Silverarc Capital Management’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.69M	Buy	+124,098	New	+$3.86M	0.43%	47

Other funds holding FTH

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Silverarc Capital Management's FTH Position: Q3 2026 in Review

Silverarc Capital Management opened a new position in Faeth Therapeutics (FTH) in Q3 2026: 124,098 shares worth $3.69M. The stake represents 0.43% of the portfolio and ranks #47 among its holdings.

42 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

Silverarc Capital Management held 124,098 shares of Faeth Therapeutics worth $3.69M as of Q3 2026.
Faeth Therapeutics was a new Silverarc Capital Management position in Q3 2026.
Faeth Therapeutics made up 0.43% of Silverarc Capital Management's portfolio in Q3 2026, its #47 holding.
42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.